Neurosurgical management and prognosis of patients with glioblastoma that progresses during bevacizumab treatment

Clinical Neurosurgery

Volumn 70, Issue 2, 2012, Pages 361-370

  Clark, Aaron J ^a   Lamborn, Kathleen R ^a   Butowski, Nicholas A ^a   Chang, Susan M ^a   Prados, Michael D ^a   Clarke, Jennifer L ^a   McDermott, Michael W ^a   Parsa, Andrew T ^a   Berger, Mitchel S ^a   Aghi, Manish K ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bevacizumab; Chemotherapy; Glioblastoma; Recurrence; Surgery; Survival

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; IRINOTECAN; LOMUSTINE; TEMOZOLOMIDE; VASCULOTROPIN; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CONTROLLED STUDY; CRANIOTOMY; FEMALE; GLIOBLASTOMA; HUMAN; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PEROPERATIVE COMPLICATION; POSTOPERATIVE CARE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SURVIVAL RATE; BRAIN TUMOR; DISEASE COURSE; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PROPORTIONAL HAZARDS MODEL; REOPERATION; TUMOR RECURRENCE; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CLINICAL OUTCOME; COMPARATIVE STUDY; MORBIDITY; PERIOPERATIVE PERIOD; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; RECURRENT DISEASE; SURGICAL PATIENT;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CRANIOTOMY; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; GLIOBLASTOMA; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROPORTIONAL HAZARDS MODELS; REOPERATION; RETROSPECTIVE STUDIES;

EID: 84859398073     PISSN: 00694827     EISSN: 0148396X     Source Type: Journal    
DOI: 10.1227/NEU.0b013e3182314f9d     Document Type: Article

References (39)

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10): 987-996.
2. Keles GE, Anderson B, Berger MS. The effect of extent of resection on time to tumor progression and survival in patients with glioblastoma multiforme of the cerebral hemisphere. Surg Neurol. 1999;52(4):371-379.
3. Keles GE, Lamborn KR, Chang SM, Prados MD, Berger MS. Volume of residual disease as a predictor of outcome in adult patients with recurrent supratentorial glioblastomas multiforme who are undergoing chemotherapy. J Neurosurg. 2004; 100(1):41-46.
4. Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg. 2001;95(2):190-198.
5. McGirt MJ, Chaichana KL, Attenello FJ, et al. Extent of surgical resection is independently associated with survival in patients with hemispheric infiltrating low-grade gliomas. Neurosurgery. 2008;63(4):700-707; author reply 707-708.
6. Stummer W, Reulen HJ, Meinel T, et al. Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery. 2008;62(3):564-576; discussion 564-576.
7. Ballman KV, Buckner JC, Brown PD, et al. The relationship between sixmonth progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. Neuro Oncol. 2007;9 (1):29-38.
8. Barbagallo GM, Jenkinson MD, Brodbelt AR. 'Recurrent' glioblastoma multiforme, when should we reoperate? Br J Neurosurg. 2008;22(3):452-455.
9. Chang SM, Parney IF, McDermott M, et al. Perioperative complications and neurological outcomes of first and second craniotomies among patients enrolled in the Glioma Outcome Project. J Neurosurg. 2003;98(6):1175-1181.
10. Sawaya R, Hammoud M, Schoppa D, et al. Neurosurgical outcomes in a modern series of 400 craniotomies for treatment of parenchymal tumors. Neurosurgery. 1998;42(5):1044-1055; discussion 1055-1056.
11. Godard S, Getz G, Delorenzi M, et al. Classification of human astrocytic gliomas on the basis of gene expression: a correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes. Cancer Res. 2003; 63(20):6613-6625.
12. Plate KH, Breier G, Weich HA, Risau W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature. 1992; 359(6398):845-848.
13. Carlson MR, Pope WB, Horvath S, et al. Relationship between survival and edema in malignant gliomas: role of vascular endothelial growth factor and neuronal pentraxin 2. Clin Cancer Res. 2007;13(9):2592-2598.
14. Lamszus K, Ulbricht U, Matschke J, Brockmann MA, Fillbrandt R, Westphal M. Levels of soluble vascular endothelial growth factor (VEGF) receptor 1 in astrocytic tumors and its relation to malignancy, vascularity, and VEGF-A. Clin Cancer Res. 2003;9(4):1399-1405.
15. Salmaggi A, Eoli M, Frigerio S, et al. Intracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma. J Neurooncol. 2003;62(3): 297-303.
16. Stefanik DF, Fellows WK, Rizkalla LR, et al. Monoclonal antibodies to vascular endothelial growth factor (VEGF) and the VEGF receptor, FLT-1, inhibit the growth of C6 glioma in a mouse xenograft. J Neurooncol. 2001;55(2):91-100.
17. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27 (28):4733-4740.
18. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009;27(5):740-745.
19. Vredenburgh JJ, Desjardins A, Herndon JE II, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 2007;13(4): 1253-1259.
20. Gutin PH, Iwamoto FM, Beal K, et al. Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys. 2009;75(1):156-163.
21. Cohen MH, Shen YL, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist. 2009;14(11):1131-1138.
22. Calland JF, Adams RB, Benjamin DK Jr, et al. Thirty-day postoperative death rate at an academic medical center. Ann Surg. 2002;235(5):690-696; discussion 696-698.
23. Du R, Lu KV, Petritsch C, et al. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell. 2008;13(3):206-220.
24. Norden AD, Drappatz J, Muzikansky A, et al. An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma. J Neurooncol. 2009;92(2): 149-155.
25. Han SJ, Yang I, Tihan T, Chang SM, Parsa AT. Secondary gliosarcoma: a review of clinical features and pathological diagnosis. J Neurosurg. 2010;112 (1):26-32.
26. Han SJ, Yang I, Otero JJ, et al. Secondary gliosarcoma after diagnosis of glioblastoma: clinical experience with 30 consecutive patients. J Neurosurg. 2010; 112(5):990-996.
27. Torcuator R, Zuniga R, Mohan YS, et al. Initial experience with bevacizumab treatment for biopsy confirmed cerebral radiation necrosis. J Neurooncol. 2009;94 (1):63-68.
28. Furuse M, Kawabata S, Kuroiwa T, Miyatake S. Repeated treatments with bevacizumab for recurrent radiation necrosis in patients with malignant brain tumors: a report of 2 cases. J Neurooncol. 2011;102(3):471-475.
29. Levin VA, Bidaut L, Hou P, et al. Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys. 2011;79(5):1487-1495.
30. Clark AJ, Butowski NA, Chang SM, et al. Impact of bevacizumab chemotherapy on craniotomy wound healing. J Neurosurg. 2011;114(6):1609-1616.
31. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28(11):1963-1972.
32. Sawlani RN, Raizer J, Horowitz SW, et al. Glioblastoma: a method for predicting response to antiangiogenic chemotherapy by using MR perfusion imaging-pilot study. Radiology. 2010;255(2):622-628.
33. Gerstner ER, Frosch MP, Batchelor TT. Diffusion magnetic resonance imaging detects pathologically confirmed, nonenhancing tumor progression in a patient with recurrent glioblastoma receiving bevacizumab. J Clin Oncol. 2010; 28(6):e91-e93.
34. Pope WB, Kim HJ, Huo J, et al. Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology. 2009; 252(1):182-189.
35. Ringelstein A, Turowski B, Gizewski ER, et al. [Evaluation of ADC mapping as an early predictor for tumor response to chemotherapy in recurrent glioma treated with bevacizumab/irinotecan: proof of principle]. Rofo. 2010;182(10):868-872.
36. Chamberlain MC, Lassman AB, Iwamoto FM. Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology. 2010;74(15): 1239-1241.
37. Grossman SA, Ye X, Piantadosi S, et al. Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clin Cancer Res. 2010;16(8): 2443-2449.
38. Lai A, Tran A, Nghiemphu PL, et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol. 2011;29(2):142-148.
39. Park JK, Hodges T, Arko L, et al. Scale to predict survival after surgery for recurrent glioblastoma multiforme. J Clin Oncol. 2010;28(24):3838-3843.